Noticias y Actividades de Eagle Pharmaceuticals

Eagle Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización EGRX (US).

Ver el organigrama con sus 30 ejecutivos principales

Biografías más buscadas en Eagle Pharmaceuticals

• Michael Graves, Interim Executive Chairman of the Board
• Robert Glenning, Director
• Jennifer Simpson, Director

Recientes movimientos de ejecutivos en Eagle Pharmaceuticals

• Debra Hussain, Head of Commercial, Acute Care and Hospital, ha dejado la empresa  (noticia publicada el 13 de mayo de 2026).

Crear su alerta
para seguir los movimientos de los ejecutivos en Eagle Pharmaceuticals.

Eagle Pharmaceuticals tiene 1.919 competidores entre los que se incluyen Sanofi (Francia), Moderna (Estados Unidos) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado el 17 de julio de 2026).
• Agenus acaba de anunciar una recaudación de fondos de 340 millones de dólares. (publicado el 17 de julio de 2026).
• GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).

Otros contactos sugeridos en el sector Farmacia

• David Ricks - President, Chief Executive Officer and Chairman of the Board en Eli Lilly
• Joaquin Duato - Chief Executive Officer and Chairman of the Board en Johnson & Johnson
• Richard Saynor - Chief Executive Officer en Sandoz

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Eagle Pharmaceuticals

• Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation | Eagle Pharmaceuticals Investor Center
• Press Releases | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection) | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke | Eagle Pharmaceuticals Investor Center
• Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury | Eagle Pharmaceuticals Investor Center
• Press Releases | Eagle Pharmaceuticals Investor Center
• View more press releases Close

Redes sociales sobre Eagle Pharmaceuticals

• Eagle Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Eagle Pharmaceuticals en LinkedIn, Twitter y YouTube